ROXYBOND (oxycodone hydrochloride) by Bayer is mu-opioid receptor, although it can bind to other opioid receptors at higher doses. Approved for pain, acute pain, chronic pain and 1 more indications. First approved in 2017.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
ROXYBOND is an oral immediate-release oxycodone hydrochloride tablet approved in 2017 for acute and chronic pain management, including osteoarthritis and opioid use disorder. It works as a mu-opioid receptor full agonist with no ceiling effect for analgesia, though clinically limited by adverse effects including respiratory and CNS depression. The precise mechanism remains incompletely understood but involves endogenous opioid receptors throughout the brain and spinal cord.
Product is approaching loss of exclusivity in 2.3 years with minimal current Part D penetration, suggesting a mature niche product with limited team expansion opportunities.
mu-opioid receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and…
Worked on ROXYBOND at Bayer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Research Study of an Investigational Drug ALO-02 (Oxycodone Hydrochloride and Naltrexone Hydrochloride) in Patients With Moderate to Severe Chronic Low Back Pain
Long-Term Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children Who Completed OTR3001
Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
ROXYBOND currently has zero linked career opportunities, reflecting its niche market position and approaching exclusivity loss. This product represents a consolidation/wind-down opportunity rather than a growth-stage career platform.